LYMPHOMAS

A standardized analyses of 2 clinical trials showed three-fourths of patients with refractory non-Hodgkin lymphoma treated with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel achieved objective responses, compared with 20% of patients who received standard therapy.

A Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMA) for axicabtagene ciloleucel (axi-cel) to treat 3 forms of non-Hodgkin lymphoma (NHL), Kite Pharma has announced.

Supplemental Biologics License Applications (sBLAs) were sent to and accepted by the FDA for a new dosing schedule for nivolumab (Opdivo) across all of the agent's indications as a montherapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor. 

Axicabtagene ciloleucel (KTE-C19; axi-cel) has been granted a priority review by the FDA for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.

Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

Martin Dreyling, MD, discusses results of the phase II CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma.

Pembrolizumab has been approved by the European Commission for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Tisagenlecleucel-T has been granted a breakthrough therapy designation by the FDA for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel has shown promising results in patients with diffuse large B-cell lymphoma, primary mediastinal lymphoma, and transformed follicular lymphoma, according to findings presented at the 2017 AACR Annual Meeting.

A majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib, according to results from the phase II CHRONOS-1 trial.<br /> &nbsp;

A retrospective analysis presented at the 2017 AACR Annual Meeting found the flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin&rsquo;s lymphoma.

More than 80% of patients with refractory non-Hodgkin lymphoma (NHL) achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (KTE-C19), according to the results of a pivotal phase II trial.

A biologics license application has been submitted for axicabtagene ciloleucel (KTE-C19) as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Patients with lymphoma who are treated with brentuximab vedotin often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with brentuximab vedotin outweigh the risk of neuropathy.&nbsp;

Pembrolizumab has been recommended for approval by the EMA&rsquo;s Committee for Medicinal Products for Human Use for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Pembrolizumab has been granted an accelerated approval by the FDA&nbsp;for the treatment of adult and pediatric patients with classical Hodgkin lymphoma who are refractory or have relapsed after 3 or more lines of therapy.

A review of various frontline treatment options in follicular lymphoma and an outline of an algorithm for approaching patients with newly diagnosed follicular lymphoma.

Nathan Fowler, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses managing patients with high-risk follicular lymphoma.

Michelle Fanale, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses patient selection for newly approved agents in T-cell lymphoma.

Results from the phase I portion of the first trial testing axicabtagene ciloleucel, an autologous CD3&zeta;/CD28-based CAR T-cell therapy, indicate that the regimen can safely be administered and lead to durable CR after more than 12 months in refractory diffuse large B-cell lymphoma.

According to results of a phase I trial, the addition of the CDK 4/6 inhibitor palbociclib can help patients with mantle cell lymphoma overcome resistance to the BTK inhibitor&nbsp;ibrutinib.

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy.

The CD19-directed CAR T-cell therapy JCAR017 demonstrated a 60% complete response (CR) rate in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma.

Alex Herrera, MD, assistant professor, City of Hope, discusses a study investigating the use of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in the treatment of relapsed or treatment-resistant Hodgkin lymphoma during the American Society of Hematology (ASH) Annual Meeting.